Yamini Natarajan1, Aylin Tansel2, Parth Patel2, Kingsley Emologu2, Richa Shukla2, Zeeshan Qureshi2, Hashem B El-Serag2,3,4,5, Aaron P Thrift2,5, Fasiha Kanwal2,3,4,5. 1. Section of Gastroenterology and Hepatology and Clinical Epidemiology and Comparative Effectiveness Program in the Health Services Research, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd (MS152), Houston, TX, 77030, USA. ynataraj@bcm.edu. 2. Section of Gastroenterology and Hepatology and Clinical Epidemiology and Comparative Effectiveness Program in the Health Services Research, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd (MS152), Houston, TX, 77030, USA. 3. Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuESt), Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, USA. 4. Texas Medical Center Digestive Disease Center, Houston, TX, USA. 5. Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: The risk and determinants of HCC in patients with primary biliary cholangitis (PBC) are unclear. We conducted a systematic review and meta-analysis of the incidence of HCC and risk factors associated with HCC risk among patients with PBC. METHODS: We searched PubMed, EMBASE, MEDLINE, Cochrane databases and reference lists from relevant articles to identify cohort studies that examined incidence of HCC in patients with PBC from inception through November 2019. RESULTS: A total of 29 studies including 22,615 patients met the eligibility criteria. The median cohort size was 292 patients followed for an average of 76 months. The pooled incidence rate for patients with PBC was 4.17 per 1000 patient-years (95% CI 3.17-5.47). On subgroup analysis, the incidence of HCC in patients with PBC cirrhosis was 15.7 per 1000 patient-years (95% CI 8.73-28.24). The HCC incidence rate was 9.82 per 1000 person-years (95% CI 5.92-16.28) in men and 3.82 per 1000 person-years (95% CI 2.85-5.11) in women. CONCLUSIONS: Cirrhosis is the strongest risk factor for HCC in patients with PBC. Male gender was also a risk factor. Our meta-analysis supports current recommendations of HCC surveillance in patients with PBC cirrhosis. Further studies are needed to evaluate risk factors in this population.
BACKGROUND: The risk and determinants of HCC in patients with primary biliary cholangitis (PBC) are unclear. We conducted a systematic review and meta-analysis of the incidence of HCC and risk factors associated with HCC risk among patients with PBC. METHODS: We searched PubMed, EMBASE, MEDLINE, Cochrane databases and reference lists from relevant articles to identify cohort studies that examined incidence of HCC in patients with PBC from inception through November 2019. RESULTS: A total of 29 studies including 22,615 patients met the eligibility criteria. The median cohort size was 292 patients followed for an average of 76 months. The pooled incidence rate for patients with PBC was 4.17 per 1000 patient-years (95% CI 3.17-5.47). On subgroup analysis, the incidence of HCC in patients with PBC cirrhosis was 15.7 per 1000 patient-years (95% CI 8.73-28.24). The HCC incidence rate was 9.82 per 1000 person-years (95% CI 5.92-16.28) in men and 3.82 per 1000 person-years (95% CI 2.85-5.11) in women. CONCLUSIONS:Cirrhosis is the strongest risk factor for HCC in patients with PBC. Male gender was also a risk factor. Our meta-analysis supports current recommendations of HCC surveillance in patients with PBC cirrhosis. Further studies are needed to evaluate risk factors in this population.
Authors: Keith D Lindor; M Eric Gershwin; Raoul Poupon; Marshall Kaplan; Nora V Bergasa; E Jenny Heathcote Journal: Hepatology Date: 2009-07 Impact factor: 17.425
Authors: Palak J Trivedi; Willem J Lammers; Henk R van Buuren; Albert Parés; Annarosa Floreani; Harry L A Janssen; Pietro Invernizzi; Pier Maria Battezzati; Cyriel Y Ponsioen; Christophe Corpechot; Raoul Poupon; Marlyn J Mayo; Andrew K Burroughs; Frederik Nevens; Andrew L Mason; Kris V Kowdley; Ana Lleo; Llorenç Caballeria; Keith D Lindor; Bettina E Hansen; Gideon M Hirschfield Journal: Gut Date: 2015-01-07 Impact factor: 23.059
Authors: Kirsten Boonstra; Robin Bokelaar; Paul H Stadhouders; Hans A Tuynman; Alexander C Poen; Karin M van Nieuwkerk; Ellen M Witteman; Dörte Hamann; Ben J Witteman; Ulrich Beuers; Cyriel Y Ponsioen Journal: Hepatol Int Date: 2014-03-28 Impact factor: 6.047
Authors: Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: BMJ Date: 2015-01-02
Authors: Fasiha Kanwal; Saira Khaderi; Amit G Singal; Jorge A Marrero; Nicole Loo; Sumeet K Asrani; Christopher I Amos; Aaron P Thrift; Xiangjun Gu; Michelle Luster; Abeer Al-Sarraj; Jing Ning; Hashem B El-Serag Journal: Hepatology Date: 2022-03-01 Impact factor: 17.298
Authors: Bonnie Bengtsson; Linnea Widman; Staffan Wahlin; Per Stål; Niklas K Björkström; Hannes Hagström Journal: United European Gastroenterol J Date: 2022-05-01 Impact factor: 6.866